AstraZeneca (AZN) Will Not Proceed with Fostamatinib; Returns Rights to Rigel (RIGL)
Tweet Send to a Friend
AstraZeneca (NYSE: AZN) announced top-line results from OSKIRA-2 and OSKIRA-3, the remaining pivotal Phase III clinical trials investigating fostamatinib ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
